Table 1. Patients Studied Patient No. .... | American Society of Hematology

Table 1.

Patients Studied

Patient No.	Mutations	Age (yr)	Duration of Therapy When Analyzed	Non-α:α Globin Chain Synthesis		Fold Increase in γ Globin mRNA on Therapy^*
Patient No.	Mutations	Age (yr)	Duration of Therapy When Analyzed	Baseline	Treatment	Fold Increase in γ Globin mRNA on Therapy^*
1	β⁺ Thalassemia	3	4 wk	0.5	0.8	3.5
	IVSI-6
	codon 39
2	β⁰ Thalassemia	41	2 wk	0.5	0.75	2.8
	Frameshift 41/42
	Frameshift 5
3	β⁰ Thalassemia	27	1 wk	0.4	0.8	3.9
	IVS I-1
	IVS II-1
4	β⁺Thalassemia	21	6 wk	0.4	0.5^-151	1.0
	codon 39/?
5	β⁺ Thalassemia	6	3 wk	0.4	0.84	3.0
	−87/codon 39
6	β⁺Thalassemia	16	4 wk	0.4	0.9	6.1
	IVS II 848
7	β⁰ Thalassemia	25	6 wk	0.47	0.86	3.1
	Homozygous
	codon 39
8	Hb SS	7	3 wk	0.5^-152	11.5^-152	5.2^-152

Patient No.	Mutations	Age (yr)	Duration of Therapy When Analyzed	Non-α:α Globin Chain Synthesis		Fold Increase in γ Globin mRNA on Therapy^*
Patient No.	Mutations	Age (yr)	Duration of Therapy When Analyzed	Baseline	Treatment	Fold Increase in γ Globin mRNA on Therapy^*
1	β⁺ Thalassemia	3	4 wk	0.5	0.8	3.5
	IVSI-6
	codon 39
2	β⁰ Thalassemia	41	2 wk	0.5	0.75	2.8
	Frameshift 41/42
	Frameshift 5
3	β⁰ Thalassemia	27	1 wk	0.4	0.8	3.9
	IVS I-1
	IVS II-1
4	β⁺Thalassemia	21	6 wk	0.4	0.5^-151	1.0
	codon 39/?
5	β⁺ Thalassemia	6	3 wk	0.4	0.84	3.0
	−87/codon 39
6	β⁺Thalassemia	16	4 wk	0.4	0.9	6.1
	IVS II 848
7	β⁰ Thalassemia	25	6 wk	0.47	0.86	3.1
	Homozygous
	codon 39
8	Hb SS	7	3 wk	0.5^-152	11.5^-152	5.2^-152

*α-Globin mRNA was used as internal control in the β-thalassemia subjects.

No changes were detected at the time that mRNA and nuclear extracts were analyzed.

Represents γ/γ + β × 100 and non-α:α-globin ratios were balanced.